Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiac Allograft Vasculopathy Clear all
Withdrawn No phase listed Observational

Severe CAV MRI in Heart Transplant Recipient

NCT02777255
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational

Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography

NCT01527344
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn Not applicable Interventional

Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients

NCT01305395
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Impact of Evolocumab in Cardiac Transplant Patients With CAV

NCT03944577
View directory record Official record
Conditions
Heart Transplant
Interventions
Evolocumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

NCT01157949
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational

Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant

NCT01403142
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Not listed No phase listed Observational

Magnetocardiography as a Noninvasive Diagnostic Strategy for Identifying Coronary Allograft Vasculopathy

NCT05751915
View directory record Official record
Conditions
Coronary Allograft Vasculopathy (CAV)
Interventions
CardioFlux
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational

Saphenous Vein Allografts for Coronary Bypass

NCT01386021
View directory record Official record
Conditions
Coronary Artery Disease, Occlusion of Artery
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Noninvasive Evaluation of Cardiac Allograft Vasculopathy

NCT01305382
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 3, 2026, 6:45 PM EDT
Terminated Phase 1 Interventional

Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation

NCT01848301
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Interventions
Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
Device · Drug · Procedure
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

NCT02880137
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Perflutren Lipid Microsphere, RTMPE
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

NCT02013037
View directory record Official record
Conditions
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy, Heart Graft Dysfunction
Interventions
Eculizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn Not applicable Interventional

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Cardiac Allograft Vasculopathy Inhibition With Alirocumab

NCT03537742
View directory record Official record
Conditions
Vasculopathy
Interventions
alirocumab, placebo
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy

NCT02082821
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational

Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation

NCT04117152
View directory record Official record
Conditions
Heart Transplantation, Allograft Arteriopathy
Interventions
Latent class mixed modeling
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn No phase listed Observational

Noninvasive Predictors of Transplant Vasculopathy

NCT01424917
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

NCT01078363
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
ramipril, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Completed No phase listed Observational

Study of Heart Transplant Rejection

NCT00042614
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 6:45 PM EDT
Withdrawn No phase listed Observational

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

NCT05756088
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Endothelial Dysfunction, Microvascular Coronary Artery Disease
Interventions
Blood draw to measure the levels of dd-cf DNA
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 3, 2026, 6:45 PM EDT
Terminated Phase 2 Interventional Results available

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

NCT01278745
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Interventions
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 3, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

NCT05373108
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 3, 2026, 6:45 PM EDT